Investor Ideas #Potcasts; #Cannabis News
and Stocks on the Move; Part 2 with K. Lance Anderson of Dickinson Wright Discussing
Cannabis IP in the U.S.
July 6th Potcast sponsored
by Lexaria Bioscience Corp. (CSE: $LXX.C) (OTC: $LXRP) and its new disruptive
drug delivery platform: DehydraTECH
Pt. Roberts, WA; Delta, BC –July 6, 2018 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca release today’s
edition of its series, Investorideas.com
potcastsCM - cannabis news and stocks to watch plus insight from
thought leaders and experts.
Listen to today’s podcast, part 2:
Read this in full at http://www.investorideas.com/news/2018/cannabis/07069Potcasts-LanceAnderson.asp
Listen to previous podcast, part one:
http://www.investorideas.com/Audio/Podcasts/2018/070218-LanceAnderson.mp3
Today’s podcast overview/transcript:
Good afternoon and welcome to another Investorideas.com potcast ;
looking at cannabis news, stocks to watch as well as insights from thought leaders
and experts. Today we will be finishing our two-part interview with K. Lance
Anderson of Dickinson Wright where we will discuss the cannabis market and the
laws surrounding it.
K. Lance Anderson has extensive experience preparing and negotiating technology
and intellectual property-focused transactions, as well as technology aspects
of mergers and acquisitions, joint ventures, and other complex commercial
transactions. A registered patent attorney, Mr. Anderson also conducts patent
prosecution, due diligence for licensing, and acquisitions, technology
agreements, strategic planning, patent prosecution, trade secrets, employment
mobility, and related operational legal issues.
Prior to private practice, Lance served for over ten years as in-house
counsel and lead intellectual property attorney for both a large public
research university system and an early stage venture capital company,
overseeing all facets of intellectual property development, management, and
transactions. His experience and background contribute to skill sets applicable
to technology transfer and emerging technology, high-tech, health-IT,
agricultural biotechnology, pharmaceuticals/life sciences, consumer products,
oil & gas, and renewable energy.
Lance represents clients within the innovation and research enterprise
including R&D, clinical and regulatory matters, strategic collaborations,
CRADA’s, manufacturing, distribution, engineering services, institutional
technology transfer, confidentiality and materials exchange, and related
alliances. In addition to representing clients on intellectual property issues,
he has been involved in many aspects of corporate law, operations, financing
and litigation ranging from start-up and early stage companies to mature market
leaders.
Dickinson Wright is positioned as one of the only full-service law firms
to welcome clients operating in this industry and to provide specialized
counsel both to clients operating with state-issued licenses and to businesses
providing goods and services to the industry.
In Part 2 of our interview with K. Lance Anderson we continue
discussing the state by state system in the US as well as the patent laws in
the cannabis market.
In regard to the
limitations or “glass ceiling” placed on the Cannabis market in the US with
expansion internationally and nationally, Anderson stated that “to have that
level of detail required for compliance, is always going to be a burden. I
think it will continue to hold back US companies that are operating in that
way.”
When asked about the
future of cannabis and what we might look forward to in the industry Anderson
went on to talk about the innovations in delivery methods. “Think about the
cannabis product as an edible. It is an oil, and it has to be metabolized by
the liver, called a first pass metabolism requirement and in essence it’s
poorly available. It’s not a very efficient process of orally administrating a
cannabis product. What you’re seeing are innovations to address that. Maybe
it’s more efficient uptake, which might mean higher bio-availability, or maybe
its stability. Maybe it’s the rapid onset of the desired effects. Those are
coming out. Someday you’re going to be able in 10 minutes to ingest something
orally and have the induced effects. On the other hand, there are antagonists
that out there. I think what we will see is the ability for a customer to
consume something for lunch and enjoy themselves and then be able to turn that
off. The ability to focus in on what I call designed delivery mechanisms to
meet everyday products and everyday users.”
We also discussed the
current state and future of patent laws regarding plant strains and breeder’s
rights. “You see the opportunity for breeder’s rights such as plant patents, to
be taken advantage of, but that doesn’t necessarily mean you won’t have access
to those innovative new lines. What it does mean is that there’s some
reasonable amount of protection from others asexually propagating that plant.
It may position these breeders to benefit for a while. But at the end of the
day can you protect the genetics of the cannabis plant from the context of
certain traits? There are various groups that want to make sure certain genomes
are sequenced and released and that will put a cushion between the innovators
and the protections they will be able to take advantage of. You will see people
take advantage of that, but I don’t think it will get to the level of the
soybean market being 90% controlled by Monsanto.”
In continuing to
discuss cannabis in comparison to agriculture and genetic modification and
plant patents. “Consumers aren’t going to accept genetically modified weed. It
just won’t happen. I think you will see it naturally balance with regard to
innovation and the protection of those innovations in contrast to people having
access to strains they want to have access to. With the extraction method and
the advent of distillate as a source material for processing oils for
vaporizers; the argument there is that it’s cleaner and that it doesn’t have
the impurities that a butane or CO2 based solvent would have. Those are selling
points. Those are well received by the industry.”
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Google Play Music, Stitcher and Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the
Investorideas.com news and stock directory pages, a cannabis investor group on
Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment